← Eichor
Condition: Adult Refractory Cancer Synced from ClinicalTrials.gov · July 30, 2026

Recruiting studies: Adult Refractory Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malign
EARLY_Phase 1 · 1 location(s) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · NCT07312630A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Phase 1 · 7 location(s) · Sairopa B.V. · NCT05856981Novel Digital Application for Patients With Acute Leukemia
NA · 3 location(s) · Massachusetts General Hospital · NCT06472128A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants
Phase 1/Phase 2 · 30 location(s) · Hoffmann-La Roche · NCT05533775Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refra
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06995872Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute
Phase 1 · 10 location(s) · St. Jude Children's Research Hospital · NCT06177067AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Phase 1/Phase 2 · 80 location(s) · AstraZeneca · NCT06137118Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633CAR-T Cell Therapy for ALL
EARLY_Phase 1 · 1 location(s) · Dr. Zaineb Akram · NCT07695012Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · 278 location(s) · National Cancer Institute (NCI) · NCT03739814Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies W
Phase N/A · 3 location(s) · National Cancer Institute (NCI) · NCT05237986Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Phase 1 · 1 location(s) · Stanford University · NCT06500819CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A
Phase 2 · 2 location(s) · KK Women's and Children's Hospital · NCT05648019Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
Phase 1 · 1 location(s) · Nationwide Children's Hospital · NCT04254419Study of GV20-0251 in Participants With Solid Tumor Malignancies
Phase 1/Phase 2 · 3 location(s) · GV20 Therapeutics · NCT07070518Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas
Phase N/A · 10 location(s) · Azienda Ospedaliera Ospedale Infantile Regina Margherita San · NCT04621201GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Phase 1 · 1 location(s) · Stanford University · NCT07087002Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Soli
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT06620302Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Phase 1 · 1 location(s) · Belarusian Research Center for Pediatric Oncology, Hematolog · NCT05333302Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplast
Phase 1/Phase 2 · 28 location(s) · National Cancer Institute (NCI) · NCT04616560CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05672147Quality of Life-Guided Transfusion in Refractory MDS or AML
NA · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT07328191Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Phase 1 · 1 location(s) · Chinese PLA General Hospital · NCT05631886FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06865664Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 7 location(s) · Nerviano Medical Sciences · NCT06549790GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Phase 1/Phase 2 · 1 location(s) · Grit Biotechnology · NCT06948981A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
Phase 1 · 2 location(s) · LaunXP Biomedical Co., Ltd. · NCT06883539AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 · 1 location(s) · Stanford University · NCT06340737AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Avelos Therapeutics Inc. · NCT06911333
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.